Medication info
Daparon Duo Sustained Release Tablet 10/500 mg

Daparon Duo Sustained Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Bis L-proline›15.6mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink, biconvex, rectangular, sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202202499 · Approved 2022.06.15 · Insurance code 643508580

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because any change may cause changes in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Blood glucose control issues in type 2 diabetes patients
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication aids in blood glucose control for patients with type 2 diabetes by utilizing a combination of dapagliflozin and metformin. It effectively manages blood glucose in conjunction with dietary and exercise interventions. Particularly suitable for adult patients with type 2 diabetes who have not adequately controlled blood glucose, and can be used cautiously in cases with cardiovascular diseases or risk factors. It is advisable to refer to professional guidelines for detailed cardiovascular-related information. This medication improves blood glucose control safely and effectively.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, the dose of this medicine may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because any change may cause changes in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and helps regulate blood glucose levels. However, it can exceptionally cause a dangerous condition called lactic acidosis, so patients with poor kidney function, severe infections, or heart disease should not use it. Caution is also needed when using it in combination with insulin or sulfonylurea as there is a risk of hypoglycemia. This medication should not be administered to patients with moderate to severe renal impairment, and temporary cessation is required in acute conditions such as dehydration, severe infections, or before and after surgery. Pregnant or breastfeeding women should not use this medication. Regular checks of kidney function, blood pressure, and fluid status should be conducted during use, particularly for the elderly or those on diuretics. This medication may cause side effects such as genital infections, urinary tract infections, hypoglycemia, dehydration, dizziness, constipation, dry mouth, low back pain, urinary pain, polyuria, nocturia, external genital itching, genital itching, increased hematocrit, decreased initial renal creatinine clearance, dyslipidemia, increased serum creatinine at the beginning of treatment, elevated blood urea, weight loss, diarrhea, nausea/vomiting, and vitamin B12 deficiency, so it is advisable to consult medical personnel if symptoms occur. Alcohol consumption can increase the risk of side effects from this medication, so excessive drinking should be avoided during treatment. This medication does not significantly affect driving or machine operation but caution is advisable due to the possibility of dizziness. Finally, store it out of reach of children and keep it in its original container to prevent misuse or degradation of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 83 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • painful urination
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • atrial fibrillation
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink, biconvex, rectangular, sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.